BACKGROUND: The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear. METHODS: We profiled gene expression in pretreatment biopsy specimens from 181 patients with diffuse large-B-cell lymphoma who received CHOP and 233 patients with this disease who received R-CHOP. A multivariate gene-expression-based survival-predictor model derived from a training group was tested in a validation group. RESULTS: A multivariate model created from three gene-expression signatures--termed "germinal-center B-cell," "stromal-1," and "stromal-2"--predicted survival both in patients who received CHOP and patients who received R-CHOP. The prognostically favorable stromal-1 signature reflected extracellular-matrix deposition and histiocytic infiltration. By contrast, the prognostically unfavorable stromal-2 signature reflected tumor blood-vessel density. CONCLUSIONS: Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment. 2008 Massachusetts Medical Society
BACKGROUND: The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear. METHODS: We profiled gene expression in pretreatment biopsy specimens from 181 patients with diffuse large-B-cell lymphoma who received CHOP and 233 patients with this disease who received R-CHOP. A multivariate gene-expression-based survival-predictor model derived from a training group was tested in a validation group. RESULTS: A multivariate model created from three gene-expression signatures--termed "germinal-center B-cell," "stromal-1," and "stromal-2"--predicted survival both in patients who received CHOP and patients who received R-CHOP. The prognostically favorable stromal-1 signature reflected extracellular-matrix deposition and histiocytic infiltration. By contrast, the prognostically unfavorable stromal-2 signature reflected tumor blood-vessel density. CONCLUSIONS: Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment. 2008 Massachusetts Medical Society
Authors: Vu N Ngo; R Eric Davis; Laurence Lamy; Xin Yu; Hong Zhao; Georg Lenz; Lloyd T Lam; Sandeep Dave; Liming Yang; John Powell; Louis M Staudt Journal: Nature Date: 2006-03-29 Impact factor: 49.962
Authors: Michael Hummel; Stefan Bentink; Hilmar Berger; Wolfram Klapper; Swen Wessendorf; Thomas F E Barth; Heinz-Wolfram Bernd; Sergio B Cogliatti; Judith Dierlamm; Alfred C Feller; Martin-Leo Hansmann; Eugenia Haralambieva; Lana Harder; Dirk Hasenclever; Michael Kühn; Dido Lenze; Peter Lichter; Jose Ignacio Martin-Subero; Peter Möller; Hans-Konrad Müller-Hermelink; German Ott; Reza M Parwaresch; Christiane Pott; Andreas Rosenwald; Maciej Rosolowski; Carsten Schwaenen; Benjamin Stürzenhofecker; Monika Szczepanowski; Heiko Trautmann; Hans-Heinrich Wacker; Rainer Spang; Markus Loeffler; Lorenz Trümper; Harald Stein; Reiner Siebert Journal: N Engl J Med Date: 2006-06-08 Impact factor: 91.245
Authors: Andrew I Su; Tim Wiltshire; Serge Batalov; Hilmar Lapp; Keith A Ching; David Block; Jie Zhang; Richard Soden; Mimi Hayakawa; Gabriel Kreiman; Michael P Cooke; John R Walker; John B Hogenesch Journal: Proc Natl Acad Sci U S A Date: 2004-04-09 Impact factor: 11.205
Authors: Antoine E Karnoub; Ajeeta B Dash; Annie P Vo; Andrew Sullivan; Mary W Brooks; George W Bell; Andrea L Richardson; Kornelia Polyak; Ross Tubo; Robert A Weinberg Journal: Nature Date: 2007-10-04 Impact factor: 49.962
Authors: Sandeep S Dave; George Wright; Bruce Tan; Andreas Rosenwald; Randy D Gascoyne; Wing C Chan; Richard I Fisher; Rita M Braziel; Lisa M Rimsza; Thomas M Grogan; Thomas P Miller; Michael LeBlanc; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Joseph M Connors; Peter M Lansdorp; Qin Ouyang; T Andrew Lister; Andrew J Davies; Andrew J Norton; H Konrad Muller-Hermelink; German Ott; Elias Campo; Emilio Montserrat; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Liming Yang; John Powell; Hong Zhao; Neta Goldschmidt; Michael Chiorazzi; Louis M Staudt Journal: N Engl J Med Date: 2004-11-18 Impact factor: 91.245
Authors: J Chiche; S Pommier; M Beneteau; L Mondragón; O Meynet; B Zunino; A Mouchotte; E Verhoeyen; M Guyot; G Pagès; N Mounier; V Imbert; P Colosetti; D Goncalvès; S Marchetti; J Brière; M Carles; C Thieblemont; J-E Ricci Journal: Leukemia Date: 2014-11-14 Impact factor: 11.528
Authors: Javeed Iqbal; Paul N Meyer; Lynette M Smith; Nathalie A Johnson; Julie M Vose; Timothy C Greiner; Joseph M Connors; Louis M Staudt; Lisa Rimsza; Elaine Jaffe; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Wing C Chan Journal: Clin Cancer Res Date: 2011-09-20 Impact factor: 12.531
Authors: Wyndham H Wilson; Sin-Ho Jung; Pierluigi Porcu; David Hurd; Jeffrey Johnson; S Eric Martin; Myron Czuczman; Raymond Lai; Jonathan Said; Amy Chadburn; Dan Jones; Kieron Dunleavy; George Canellos; Andrew D Zelenetz; Bruce D Cheson; Eric D Hsi Journal: Haematologica Date: 2011-12-01 Impact factor: 9.941
Authors: Alex J Cornish; Phuc H Hoang; Sara E Dobbins; Philip J Law; Daniel Chubb; Giulia Orlando; Richard S Houlston Journal: Blood Adv Date: 2019-01-08
Authors: Tint Lwin; Xiaohong Zhao; Fengdong Cheng; Xinwei Zhang; Andy Huang; Bijal Shah; Yizhuo Zhang; Lynn C Moscinski; Yong Sung Choi; Alan P Kozikowski; James E Bradner; William S Dalton; Eduardo Sotomayor; Jianguo Tao Journal: J Clin Invest Date: 2013-11 Impact factor: 14.808